Ophthalmology

Our client, a pharmaceutical company, sought insights into the dynamics of the ophthalmology market in France, particularly concerning the potential replacement of Lucentis or Avastin in the treatment of Age-Related Macular Degeneration (AMD) with a new Monoclonal Antibody (MAB). With the prevalence of off-label usage of Avastin due to cost considerations, understanding the landscape and receptiveness to new treatments posed a significant challenge.